Download PDF
Thorac Cardiovasc Surg 2018; 66(01): 053-062
DOI: 10.1055/s-0037-1608761
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Regenerative Medicine/Cardiac Cell Therapy: Pluripotent Stem Cells

Ana G. Duran
1   Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Olivia Reidell
1   Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Harald Stachelscheid
1   Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
2   Berlin Institute of Health, Berlin, Germany
,
Kristin Klose
1   Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Manfred Gossen
1   Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
,
Volkmar Falk
3   DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
4   Deutsches Herzzentrum Berlin, Berlin, Germany
,
Wilhelm Röll
5   Klinik für Herzchirurgie, Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen Germany
,
Christof Stamm
1   Universitätsmedizin Berlin, Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany
3   DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany
4   Deutsches Herzzentrum Berlin, Berlin, Germany
› Author Affiliations
Further Information

Publication History

27 June 2017

12 October 2017

Publication Date:
07 December 2017 (online)

    Permissions and Reprints All articles of this category

Abstract

For more than 20 years, tremendous efforts have been made to develop cell-based therapies for treatment of heart failure. However, the results of clinical trials using somatic, nonpluripotent stem or progenitor cells have been largely disappointing in both cardiology and cardiac surgery scenarios. Surgical groups were among the pioneers of experimental and clinical myocyte transplantation (“cellular cardiomyoplasty”), but little translational progress was made prior to the development of cellular reprogramming for creation of induced pluripotent stem cells (iPSC). Ever since, protocols have been developed which allow for the derivation of large numbers of autologous cardiomyocytes (CMs) from patient-specific iPSC, moving translational research closer toward clinical pilot trials. However, compared with somatic cell therapy, the technology required for safe and efficacious pluripotent stem cell (PSC)-based therapies is extremely complex and requires tremendous resources and close interactions between basic scientists and clinicians. This review summarizes PSC sources, strategies to derive CMs, current cardiac tissue engineering approaches, concerns regarding immunogenicity and cellular maturity, and highlights the contributions made by surgical groups.

Keywords

cell - biology - culture - experimental - stem cells - heart failure - tissue engineering
 

  • References

  • 1 Li RK, Jia ZQ, Weisel RD. , et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996; 62 (03) 654-660 , discussion 660–661
    CrossrefPubMedGoogle Scholar
  • 2 Léobon B, Garcin I, Menasché P, Vilquin J-T, Audinat E, Charpak S. Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. Proc Natl Acad Sci U S A 2003; 100 (13) 7808-7811
    CrossrefPubMedGoogle Scholar
  • 3 Makino S, Fukuda K, Miyoshi S. , et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103 (05) 697-705
    CrossrefPubMedGoogle Scholar
  • 4 Fisher SA, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 2016; 12: CD007888
    PubMedGoogle Scholar
  • 5 Behfar A, Perez-Terzic C, Faustino RS. , et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med 2007; 204 (02) 405-420
    CrossrefPubMedGoogle Scholar
  • 6 Menasché P, Vanneaux V, Hagège A. , et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J 2015; 36 (30) 2011-2017
    CrossrefPubMedGoogle Scholar
  • 7 Tachibana M, Amato P, Sparman M. , et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 2013; 153 (06) 1228-1238
    CrossrefPubMedGoogle Scholar
  • 8 Revazova ES, Turovets NA, Kochetkova OD. , et al. Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells 2007; 9 (03) 432-449
    CrossrefPubMedGoogle Scholar
  • 9 Evans MJ, Gurer C, Loike JD, Wilmut I, Schnieke AE, Schon EA. Mitochondrial DNA genotypes in nuclear transfer-derived cloned sheep. Nat Genet 1999; 23 (01) 90-93
    CrossrefPubMedGoogle Scholar
  • 10 Takahashi K, Tanabe K, Ohnuki M. , et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131 (05) 861-872
    CrossrefPubMedGoogle Scholar
  • 11 Al Kindi A, Ge Y, Shum-Tim D, Chiu RC. Cellular cardiomyoplasty: routes of cell delivery and retention. Front Biosci 2008; 13: 2421-2434
    CrossrefPubMedGoogle Scholar
  • 12 Malik N, Rao MS. A review of the methods for human iPSC derivation. Methods Mol Biol 2013; 997: 23-33
    PubMedGoogle Scholar
  • 13 Kim K, Doi A, Wen B. , et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467 (7313): 285-290
    CrossrefPubMedGoogle Scholar
  • 14 Mayshar Y, Ben-David U, Lavon N. , et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7 (04) 521-531
    CrossrefPubMedGoogle Scholar
  • 15 Laurent LC, Ulitsky I, Slavin I. , et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8 (01) 106-118
    CrossrefPubMedGoogle Scholar
  • 16 Zhao T, Zhang Z-N, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474 (7350): 212-215
    CrossrefPubMedGoogle Scholar
  • 17 González F, Boué S, Izpisúa Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming à la carte. Nat Rev Genet 2011; 12 (04) 231-242
    PubMedGoogle Scholar
  • 18 Chang C-W, Lai Y-S, Pawlik KM. , et al. Polycistronic lentiviral vector for “hit and run” reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009; 27 (05) 1042-1049
    CrossrefPubMedGoogle Scholar
  • 19 Stadtfeld M, Maherali N, Breault DT, Hochedlinger K. Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. Cell Stem Cell 2008; 2 (03) 230-240
    CrossrefPubMedGoogle Scholar
  • 20 Soldner F, Hockemeyer D, Beard C. , et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136 (05) 964-977
    CrossrefPubMedGoogle Scholar
  • 21 Woltjen K, Michael IP, Mohseni P. , et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458 (7239): 766-770
    CrossrefPubMedGoogle Scholar
  • 22 Diecke S, Lu J, Lee J. , et al. Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. Sci Rep 2015; 5 (01) 8081
    CrossrefPubMedGoogle Scholar
  • 23 Warren L, Manos PD, Ahfeldt T. , et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7 (05) 618-630
    CrossrefPubMedGoogle Scholar
  • 24 Kim D, Kim C-H, Moon J-I. , et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4 (06) 472-476
    CrossrefPubMedGoogle Scholar
  • 25 Hou P, Li Y, Zhang X. , et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341 (6146): 651-654
    CrossrefPubMedGoogle Scholar
  • 26 Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad, Ser B, Phys Biol Sci 2009; 85 (08) 348-362
    CrossrefPubMedGoogle Scholar
  • 27 Kehat I, Kenyagin-Karsenti D, Snir M. , et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001; 108 (03) 407-414
    CrossrefPubMedGoogle Scholar
  • 28 Talkhabi M, Aghdami N, Baharvand H. Human cardiomyocyte generation from pluripotent stem cells: a state-of-art. Life Sci 2016; 145: 98-113
    CrossrefPubMedGoogle Scholar
  • 29 Chong JJ, Yang X, Don CW. , et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014; 510 (7504): 273-277
    CrossrefPubMedGoogle Scholar
  • 30 Molina DK, DiMaio VJ. Normal organ weights in men: part I-the heart. Am J Forensic Med Pathol 2012; 33 (04) 362-367
    CrossrefPubMedGoogle Scholar
  • 31 Lian X, Hsiao C, Wilson G. , et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 2012; 109 (27) E1848-E1857
    CrossrefPubMedGoogle Scholar
  • 32 Kempf H, Andree B, Zweigerdt R. Large-scale production of human pluripotent stem cell derived cardiomyocytes. Adv Drug Deliv Rev 2016; 96: 18-30
    CrossrefPubMedGoogle Scholar
  • 33 Anderson D, Self T, Mellor IR, Goh G, Hill SJ, Denning C. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Ther 2007; 15 (11) 2027-2036
    CrossrefPubMedGoogle Scholar
  • 34 Bizy A, Guerrero-Serna G, Hu B. , et al. Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes. Stem Cell Res (Amst) 2013; 11 (03) 1335-1347
    CrossrefPubMedGoogle Scholar
  • 35 Uosaki H, Fukushima H, Takeuchi A. , et al. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One 2011; 6 (08) e23657
    CrossrefPubMedGoogle Scholar
  • 36 Dubois NC, Craft AM, Sharma P. , et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 2011; 29 (11) 1011-1018
    CrossrefPubMedGoogle Scholar
  • 37 Tohyama S, Hattori F, Sano M. , et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013; 12 (01) 127-137
    CrossrefPubMedGoogle Scholar
  • 38 Hattori F, Chen H, Yamashita H. , et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 2010; 7 (01) 61-66
    CrossrefPubMedGoogle Scholar
  • 39 Ben-David U, Gan QF, Golan-Lev T. , et al. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell 2013; 12 (02) 167-179
    CrossrefPubMedGoogle Scholar
  • 40 van Laake LW, Passier R, Monshouwer-Kloots J. , et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res (Amst) 2007; 1 (01) 9-24
    CrossrefPubMedGoogle Scholar
  • 41 Laflamme MA, Chen KY, Naumova AV. , et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007; 25 (09) 1015-1024
    CrossrefPubMedGoogle Scholar
  • 42 Caspi O, Huber I, Kehat I. , et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardial performance in infarcted rat hearts. J Am Coll Cardiol 2007; 50 (19) 1884-1893
    CrossrefPubMedGoogle Scholar
  • 43 Shiba Y, Fernandes S, Zhu W-Z. , et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 2012; 489 (7415): 322-325
    CrossrefPubMedGoogle Scholar
  • 44 Shiba Y, Gomibuchi T, Seto T. , et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 2016; 538 (7625): 388-391
    CrossrefPubMedGoogle Scholar
  • 45 Li L, Baroja ML, Majumdar A. , et al. Human embryonic stem cells possess immune-privileged properties. Stem Cells 2004; 22 (04) 448-456
    CrossrefPubMedGoogle Scholar
  • 46 Fairchild PJ. The challenge of immunogenicity in the quest for induced pluripotency. Nat Rev Immunol 2010; 10 (12) 868-875
    CrossrefPubMedGoogle Scholar
  • 47 Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013; 12 (04) 407-412
    CrossrefPubMedGoogle Scholar
  • 48 Araki R, Uda M, Hoki Y. , et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013; 494 (7435): 100-104
    CrossrefPubMedGoogle Scholar
  • 49 Todorova D, Kim J, Hamzeinejad S, He J, Xu Y. Brief report: immune microenvironment determines the immunogenicity of induced pluripotent stem cell derivatives. Stem Cells 2016; 34 (02) 510-515
    CrossrefPubMedGoogle Scholar
  • 50 Liu Z, Wen X, Wang H. , et al. Molecular imaging of induced pluripotent stem cell immunogenicity with in vivo development in ischemic myocardium. PLoS One 2013; 8 (06) e66369
    CrossrefPubMedGoogle Scholar
  • 51 Zhao T, Zhang ZN, Westenskow PD. , et al. Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell 2015; 17 (03) 353-359
    CrossrefPubMedGoogle Scholar
  • 52 Suárez-Alvarez B, Rodriguez RM, Calvanese V. , et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS One 2010; 5 (04) e10192
    CrossrefPubMedGoogle Scholar
  • 53 Tso GH, He J, Chan CW. Engineering of the immune system for human ESC- and iPSC-derived grafts. Drug Discov Today Dis Models 2012; 9 (04) e171-e178 Available at https://doi.org/10.1016/j.ddmod . Accessed September 2, 2012
    CrossrefPubMedGoogle Scholar
  • 54 Wilmut I, Leslie S, Martin NG. , et al. Development of a global network of induced pluripotent stem cell haplobanks. Regen Med 2015; 10 (03) 235-238
    CrossrefPubMedGoogle Scholar
  • 55 Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat Biotechnol 2008; 26 (07) 739-740
    CrossrefPubMedGoogle Scholar
  • 56 Brodarac A, Šarić T, Oberwallner B. , et al. Susceptibility of murine induced pluripotent stem cell-derived cardiomyocytes to hypoxia and nutrient deprivation. Stem Cell Res Ther 2015; 6: 83
    CrossrefPubMedGoogle Scholar
  • 57 Robertson C, Tran DD, George SC. Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes. Stem Cells 2013; 31 (05) 829-837
    CrossrefPubMedGoogle Scholar
  • 58 Martherus RS, Vanherle SJ, Timmer ED. , et al. Electrical signals affect the cardiomyocyte transcriptome independently of contraction. Physiol Genomics 2010; 42A (04) 283-289
    CrossrefPubMedGoogle Scholar
  • 59 Földes G, Mioulane M, Wright JS. , et al. Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy?. J Mol Cell Cardiol 2011; 50 (02) 367-376
    CrossrefPubMedGoogle Scholar
  • 60 Lee Y-K, Ng K-M, Chan Y-C. , et al. Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway. Mol Endocrinol 2010; 24 (09) 1728-1736
    CrossrefPubMedGoogle Scholar
  • 61 Wang H, Zhou J, Liu Z, Wang C. Injectable cardiac tissue engineering for the treatment of myocardial infarction. J Cell Mol Med 2010; 14 (05) 1044-1055
    PubMedGoogle Scholar
  • 62 Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: state of the art. Circ Res 2014; 114 (02) 354-367
    CrossrefPubMedGoogle Scholar
  • 63 Pecha S, Eschenhagen T, Reichenspurner H. Myocardial tissue engineering for cardiac repair. J Heart Lung Transplant 2016; 35 (03) 294-298
    CrossrefPubMedGoogle Scholar
  • 64 Khan M, Xu Y, Hua S. , et al. Evaluation of changes in morphology and function of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) cultured on an aligned-nanofiber cardiac patch. PLoS One 2015; 10 (05) e0126338
    CrossrefPubMedGoogle Scholar
  • 65 Chen QZ, Ishii H, Thouas GA. , et al. An elastomeric patch derived from poly(glycerol sebacate) for delivery of embryonic stem cells to the heart. Biomaterials 2010; 31 (14) 3885-3893
    CrossrefPubMedGoogle Scholar
  • 66 Maitz MF. Applications of synthetic polymers in clinical medicine. Biosurface and Biotribology. 2015; 1 (03) 161-176
    CrossrefPubMedGoogle Scholar
  • 67 Schaaf S, Shibamiya A, Mewe M. , et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 2011; 6 (10) e26397
    CrossrefPubMedGoogle Scholar
  • 68 Ruan JL, Tulloch NL, Saiget M. , et al. Mechanical stress promotes maturation of human myocardium from pluripotent stem cell-derived progenitors. Stem Cells 2015; 33 (07) 2148-2157
    CrossrefPubMedGoogle Scholar
  • 69 Wendel JS, Ye L, Tao R. , et al. Functional effects of a tissue-engineered cardiac patch from human induced pluripotent stem cell-derived cardiomyocytes in a rat infarct model. Stem Cells Transl Med 2015; 4 (11) 1324-1332
    CrossrefPubMedGoogle Scholar
  • 70 Weinberger F, Breckwoldt K, Pecha S. , et al. Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci Transl Med 2016; 8 (363) 363ra148
    CrossrefPubMedGoogle Scholar
  • 71 Tulloch NL, Muskheli V, Razumova MV. , et al. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ Res 2011; 109 (01) 47-59
    CrossrefPubMedGoogle Scholar
  • 72 Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010; 123 (Pt 24): 4195-4200
    CrossrefPubMedGoogle Scholar
  • 73 Stamm C, Nasseri B, Choi Y-H, Hetzer R. Cell therapy for heart disease: great expectations, as yet unmet. Heart Lung Circ 2009; 18 (04) 245-256
    CrossrefPubMedGoogle Scholar
  • 74 Joggerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Expert Rev Mol Med 2009; 11: e20
    CrossrefPubMedGoogle Scholar
  • 75 Ott HC, Matthiesen TS, Goh S-K. , et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 2008; 14 (02) 213-221
    CrossrefPubMedGoogle Scholar
  • 76 Sarig U, Au-Yeung GCT, Wang Y. , et al. Thick acellular heart extracellular matrix with inherent vasculature: a potential platform for myocardial tissue regeneration. Tissue Eng Part A 2012; 18 (19-20): 2125-2137
    CrossrefPubMedGoogle Scholar
  • 77 Oberwallner B, Brodarac A, Choi YH. , et al. Preparation of cardiac extracellular matrix scaffolds by decellularization of human myocardium. J Biomed Mater Res A 2014; 102 (09) 3263-3272
    CrossrefPubMedGoogle Scholar
  • 78 Oberwallner B, Brodarac A, Anić P. , et al. Human cardiac extracellular matrix supports myocardial lineage commitment of pluripotent stem cells. Eur J Cardiothorac Surg 2015; 47 (03) 416-425 , discussion 425
    CrossrefPubMedGoogle Scholar
  • 79 Seetapun D, Ross JJ. Eliminating the organ transplant waiting list: the future with perfusion decellularized organs. Surgery 2017; 161 (06) 1474-1478
    CrossrefPubMedGoogle Scholar
  • 80 Lu T-Y, Lin B, Kim J. , et al. Repopulation of decellularized mouse heart with human induced pluripotent stem cell-derived cardiovascular progenitor cells. Nat Commun 2013; 4: 2307
    CrossrefPubMedGoogle Scholar
  • 81 Matsuura K, Utoh R, Nagase K, Okano T. Cell sheet approach for tissue engineering and regenerative medicine. J Control Release 2014; 190: 228-239
    CrossrefPubMedGoogle Scholar
  • 82 Kawamura M, Miyagawa S, Miki K. , et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012; 126 (11) (Suppl. 01) S29-S37
    CrossrefPubMedGoogle Scholar
  • 83 Chang D, Wen Z, Wang Y. , et al. Ultrastructural features of ischemic tissue following application of a bio-membrane based progenitor cardiomyocyte patch for myocardial infarction repair. PLoS One 2014; 9 (10) e107296
    CrossrefPubMedGoogle Scholar
  • 84 Kempf H, Kropp C, Olmer R, Martin U, Zweigerdt R. Cardiac differentiation of human pluripotent stem cells in scalable suspension culture. Nat Protoc 2015; 10 (09) 1345-1361
    CrossrefPubMedGoogle Scholar
  • 85 Chen JX, Krane M, Deutsch MA. , et al. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res 2012; 111 (01) 50-55
    CrossrefPubMedGoogle Scholar
  • 86 Tiburcy M, Hudson JE, Balfanz P. , et al. Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair. Circulation 2017; 135 (19) 1832-1847
    CrossrefPubMedGoogle Scholar
  • 87 Weinberger F, Mannhardt I, Eschenhagen T. Engineering cardiac muscle tissue: a maturating field of research. Circ Res 2017; 120 (09) 1487-1500
    CrossrefPubMedGoogle Scholar